Muscle loss severity is related to tumour type, size, location in mice

Pennsylvania [US], December 2 (ANI): Approximately 80 per cent of cancer patients experience substantial muscle wasting or loss of muscular tissue, and 30 per cent of these individuals die as a result of this illness. According to new mouse research, the severity of muscle wasting is related to the kind, size, and location of the tumour.
“Muscle wasting, and not the tumour itself, is often the killer,” said Gustavo Nader, associate professor of kinesiology, Penn State. “That’s why it is important to study what is happening at the cellular level in skeletal muscle that may be contributing to the wasting problem.”
Nader’s previous research in ovarian cancer revealed that muscle wasting is related to reduced production of ribosomes — or particles in the cell that make proteins. Yet, he said, relatively little is known about the mechanisms driving down muscle protein synthesis and wasting in cancer patients.
In new research published in two papers appearing in the same issue of the Journal of Applied Physiology, the team investigated the mechanisms involved in muscle wasting in lung cancer and colorectal cancer in mice. The researchers found that the type, size and location of the tumour influenced the severity of muscle wasting through divergent mechanisms.
In the lung cancer study, the team examined the effects of two different types of lung cancer-derived tumours — LP07 and Lewis lung carcinoma (LLC). Tumour growth resulted in significant muscle weakness in mice with the LP07 tumour type, which was also associated with a reduction in ribosome production, while muscle wasting in the LLC tumour type caused muscle wasting but did not produce weakness or lowered ribosomal levels.
In the colorectal cancer study, the team examined two types of colorectal tumours — HCT116 and C26 — and studied them using two models to define the role of tumour burden on muscle wasting. Tumour burden is the number of cancer cells, the size of a tumour, the amount of cancer in the body or the disease severity associated with the tumour. The findings indicate that the location of the tumour is an important factor in determining the severity of muscle wasting but this also depends on the type of tumour.
“There are no effective treatments for muscle wasting in cancer patients,” said Nader. “We are beginning to understand how different tumours cause muscle wasting, which is crucial because cancer treatments are less effective in patients with low muscle mass.”
The Penn State team collaborated with David Waning from Hershey Medical Center, Esther Barreiro from the Universitat Pompeu Fabra in Barcelona, and Andrea Bonetto from Indiana University. Research in the Nader lab is supported by The National Institutes of Health. (ANI)